4D Molecular Therapeutics Inc (NAS:FDMT)
$ 8.39 0.215 (2.63%) Market Cap: 436.02 Mil Enterprise Value: -103.44 Mil PE Ratio: 0 PB Ratio: 0.74 GF Score: 63/100

4D Molecular Therapeutics Inc 4D-710 Phase 1/2 AEROW Interim Clinical Data Call Transcript

Jun 07, 2023 / 08:30PM GMT
Release Date Price: $18.27 (-4.94%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to 4D Molecular Therapeutics webcast presentation of Interim Safety and Efficacy Data from the Phase 1 AEROW Clinical Trial of Aerosolized 4D-710 in patients with Cystic Fibrosis Lung Disease. (Operator Instructions). As a reminder, today's call is being recorded.

With that, I will hand the call over to August Moretti, Chief Financial Officer, who will make introductory comments.

August J. Moretti
4D Molecular Therapeutics, Inc. - CFO

Thank you, operator, and welcome, everyone, to 4D Molecular Therapeutics' 4D-710 interim data webcast. A press release describing the results and development plans related to 4D-710 is accessible in the Investors section of the 4D Molecular Therapeutics website, and a recording of this webcast will be accessible on our website after completion of this call.

With me today are: Dr. David Kirn, our Co-Founder and Chief Executive Officer; and Dr. Jennifer Taylor-Cousar, Professor, Departments of Medicine and Pediatrics, and Co-Director, Adult Cystic

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot